Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy

  • Raj G
  • Partin A
  • Polascik T
  • 15

    Readers

    Mendeley users who have this article in their library.
  • 80

    Citations

    Citations of this article.

Abstract

Despite the ability of radical prostatectomy to eradicate prostate carcinoma, biochemical evidence of recurrent prostate carcinoma may be seen in approximately 40% of patients 15 years after they undergo surgery. Localization of recurrent disease after radical prostatectomy is difficult and may greatly influence subsequent clinical management. The authors examined the utility of indium 111 ((111)In)-capromab pendetide immunoscintigraphy to detect recurrent prostate carcinoma radiographically in men with early biochemical evidence of failure (serum prostate specific antigen [PSA] < or = 4.0 ng/mL) and assessed the minimum serum PSA level necessary for imaging recurrent disease.

Author-supplied keywords

  • Biochemical progression
  • Capromab pendetide
  • ProstaScint
  • Prostate specific antigen
  • Radical prostatectomy
  • Recurrence

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Ganesh V. Raj

  • Alan W. Partin

  • Thomas J. Polascik

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free